*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

# Fusen Pharmaceutical Company Limited
# 福森藥業有限公司

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1652)**

## VOLUNTARY ANNOUNCEMENT
## SELECTION RESULTS OF
## NATIONAL CENTRALISED MEDICINES PROCUREMENT

The board of directors (the "**Board**") of Fusen Pharmaceutical Company Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that one of the Group's products was selected in the tender results of the eleventh batch of the National Centralised Medicines Procurement (全國藥品集中採購) in China on 27 October 2025: Metformin Empagliflozin Tablets (I) (metformin hydrochloride 500 mg and empagliflozin 5 mg).

This announcement is made by the Company on a voluntary basis for the purpose of keeping the shareholders and potential investors informed of the latest business developments of the Group.

By order of the Board
**Fusen Pharmaceutical Company Limited**
**Mr. Cao Zhiming**
*Chairman and Executive Director*

Hong Kong, 30 October 2025

*As at the date of this announcement, the Board of the Company comprises Mr. Cao Zhiming (Chairman), Mr. Hou Taisheng, Mr. Chi Yongsheng and Ms. Meng Qingfen as executive Directors and Mr. Lee Kwok Tung Louis, Dr. To Kit Wa and Mr. Yu Ho Ming as independent non-executive Directors.*